✦ LIBER ✦

Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding

✍ Scribed by George Mantzios; Panagiotis Tsirigotis; Vassiliki Pappa; Konstantina Spirou; Vassiliki Giannopoulou; Irene Kaitsa; Konstantinos Girkas; Efstathios Papageorgiou; John Dervenoulas

Book ID: 114794133
Publisher: John Wiley and Sons
Year: 2006
Tongue: English
Weight: 450 KB
Volume: 78
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2006.00799.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Massive postpartum hemorrhage after chem

Massive postpartum hemorrhage after chemotherapy in a patient with acute promyelocytic leukemia

✍ Aiko Aoki; Noriko Yoneda; Satoshi Yoneda; Takayoshi Miyazono; Toshiro Sugiyama; 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 492 KB

Tumor lysis syndrome after starting trea

Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia

✍ A. Al-Kali; S. Farooq; A. Tfayli 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 68 KB

Delayed intracardial shunting and hypoxe

Delayed intracardial shunting and hypoxemia after massive pulmonary embolism in a patient with a biventricular assist device

✍ Thomas Weig; Michael E Dolch; Lorenz Frey; Dirk Bruegger; Peter Boekstegers; Ral 📂 Article 📅 2011 🏛 BioMed Central 🌐 English ⚖ 590 KB

Withholding treatment in patients with a

Withholding treatment in patients with acute pulmonary embolism who have a high risk of bleeding and negative serial noninvasive leg tests

✍ Paul D Stein; Russell D Hull; Gary E Raskob 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 73 KB

Possible association between Budd-Chiari

Possible association between Budd-Chiari syndrome and gemtuzumab ozogamicin treatment in a patient with refractory acute myelogenous leukemia

✍ Mevlüt Kurt; Ali Shorbagi; Kadri Altundag; Tamer Elkiran; Ibrahim Güllü; Emin Ka 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB 👁 2 views

## Abstract Gemtuzumab ozogamicin (GO; CMA‐676; Mylotarg™) is a chemotherapeutic agent approved for the treatment of CD33‐positive acute myelogenous leukemia in patients of age 60 years or older after first relapse. Hepatic veno‐occlusive disease has been reported to develop as a late complication

Leuconostoc septicemia in a neutropenic

Leuconostoc septicemia in a neutropenic patient with acute myelogenous leukemia relapsed after allogeneic peripheral blood stem cell transplantation

✍ R. Yamazaki; T. Mori; K. Sugita; Y. Aisa; Y. Ikeda; S. Okamoto 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB